NASDAQ$IRD
Opus Genetics Inc · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2025 and provided a corporate update.
Opus Genetics reported a net loss of $8.2 million for the first quarter of 2025, compared to a net loss of $7.1 million in the same period last year. Revenue increased to $4.4 million, primarily from a collaboration agreement. The company ended the quarter with $41.8 million in cash and cash equivalents.
- License and collaborations revenue increased to $4.4 million in Q1 2025, up from $1.7 million in Q1 2024.
- Net loss for Q1 2025 was $8.2 million, or $(0.24) per share, compared to a net loss of $7.1 million, or $(0.29) per share, in Q1 2024.
- General and administrative expenses increased to $6.3 million in Q1 2025 from $4.7 million in Q1 2024.
- Research and development expenses rose to $8.0 million in Q1 2025 from $4.7 million in Q1 2024.
Headline financials
Revenue & EPS history
Ocuphire · Revenue · Quarterly
$4.37M
Revenue by segment
Ocuphire · $100K total across 1 segment · Q2 2021
- Collaboration Revenue$100K—100.0%
Forward guidance
Opus Genetics expects initial data from the pediatric cohort of the OPGx-LCA5 trial in Q3 2025, plans to file an IND and initiate a Phase 1/2 trial for OPGx-BEST1 in 2025 with preliminary data in Q1 2026, and anticipates topline data from Phase 3 trials for Phentolamine Ophthalmic Solution 0.75% in mid-2025 and the first half of 2025.
Tailwinds
- Initial data from OPGx-LCA5 pediatric cohort expected in Q3 2025.
- IND filing and initiation of Phase 1/2 trial for OPGx-BEST1 planned for 2025.
- Preliminary data from OPGx-BEST1 trial expected in Q1 2026.
- Topline data from LYNX-2 Phase 3 trial expected mid-year 2025.
- Topline data from VEGA-3 Phase 3 trial expected in the first half of 2025.
Headwinds
- Clinical data are preliminary and from a small patient group, subject to revision or invalidation.
- Failure to successfully integrate businesses after the Opus Acquisition could have a material adverse effect.
- Gene therapy candidates are based on novel technology that is difficult to develop and manufacture.
- Planned clinical trials may face substantial delays, failure, or provide inconclusive/adverse results.
- Delays or difficulties with patient enrollment in clinical trials may affect ability to complete trials and obtain regulatory approvals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-3.6%
Avg return
Earnings day
-3.8%
Avg return
5 days after
-3.1%
Avg return
30 days after
42%
14 / 33 earnings
Positive
+16.7%
Q1 2017
Best reaction
-47.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -6.1% | — | |
| Q4 2025 | +1.7% | +5.5% | +15.3% | |
| Q3 2025 | -3.1% | -11.7% | +19.8% | |
| Q2 2025 | +7.4% | +0.9% | +25.5% | |
| Q1 2025 | +7.5% | +4.2% | +2.1% | |
| Q3 2024 | -7.7% | -9.4% | -5.1% | |
| Q2 2024 | -24.7% | -19.9% | -24.1% | |
| Q1 2024 | -14.3% | -11.7% | -13.8% | |
| Q4 2023 | -12.2% | -13.9% | -19.7% | |
| Q3 2023 | +13.4% | +3.5% | -4.9% | |
| Q2 2023 | +0.5% | +0.7% | -3.1% | |
| Q1 2023 | -18.9% | -28.0% | -36.0% | |
| Q4 2022 | +4.2% | +44.2% | +42.5% | |
| Q3 2022 | -2.8% | +13.1% | +52.3% | |
| Q2 2022 | -9.7% | -6.1% | -14.3% | |
| Q1 2022 | +8.5% | +6.5% | +5.5% | |
| Q4 2021 | +11.1% | -9.9% | -35.9% | |
| Q3 2021 | -0.3% | -10.9% | -5.6% | |
| Q2 2021 | -8.5% | -14.7% | -0.6% | |
| Q1 2021 | -7.8% | -5.9% | +17.4% | |
| Q4 2020 | -12.7% | -7.8% | -34.7% | |
| Q3 2020 | +1.4% | -10.8% | -22.4% | |
| Q2 2020 | -1.6% | +1.2% | -25.9% | |
| Q1 2020 | -16.4% | -2.7% | +3.8% | |
| Q3 2019 | -5.9% | -9.3% | -11.2% | |
| Q2 2019 | -47.3% | -49.3% | -54.8% | |
| Q1 2019 | -10.4% | -11.0% | -10.3% | |
| Q2 2018 | +2.7% | +5.4% | +17.0% | |
| Q4 2018 | -2.9% | -3.5% | -4.7% | |
| Q3 2017 | +4.9% | +6.5% | +15.7% | |
| Q2 2017 | +5.9% | -1.6% | +26.5% | |
| Q1 2017 | +16.7% | +29.2% | -10.4% | |
| Q2 2016 | +0.0% | -3.7% | -3.7% | |
| Q1 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro